GE Healthcare Technologies Inc (GEHC) FinancialsGEHCGE Healthcare Technologies Inc

GE HealthCare Technologies Inc. (GEHC) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Total AIS, accounting for 171.2% of total sales, equivalent to $9.07B. Other significant revenue streams include Total PDx and Total PCS. Understanding this composition is critical for investors evaluating how GEHC navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, GE HealthCare Technologies Inc. maintains a gross margin of 41.17%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 16.58%, while the net margin is 10.82%. These profitability ratios, combined with a Return on Equity (ROE) of 19.19%, provide a clear picture of how effectively GEHC converts its operational activities into shareholder value.

In the context of the broader market, GEHC competes directly with industry leaders such as ILMN and DXCM. With a market capitalization of $33.28B, it holds a significant position in the sector. When comparing efficiency, GEHC's gross margin of 41.17% stands against ILMN's 66.44% and DXCM's 63.44%. Such benchmarking helps identify whether GE HealthCare Technologies Inc. is trading at a premium or discount relative to its financial performance.

The company has shown stable revenue growth, with Q2 2026 revenue at $5.295 billion and a gross margin of 41.17%. However, net income has fluctuated, with Q2 2026 net income at $561 million.